Meeting Banner
Abstract #0203

Apparent diffusion coefficient as a non-contrast marker of residual disease after breast neoadjuvant treatment

Patrick J Bolan1, Wen Li2, Bonnie N Joe2, Nu Le2, Elissa Price2, Jessica Gibbs2, Lisa J Wilmes2, Debsmita Biswas3, Anum Kazerouni3, An L Church4, Elizabeth S McDonald5, Stephane Loubrie6, Rebecca Rakow-Penner6, Hon J Yu6, Dariya Malyarenko7, Thomas L Chenervert7, Beatriu Reig8, Nola M Hylton2, and Savannah Partridge3
1Center for MR Research / Radiology, University of Minnesota, MINNEAPOLIS, MN, United States, 2Radiology, University of California San Francisco, San Francisco, CA, United States, 3University of Washington, Seattle, WA, United States, 4Radiology, University of Minnesota, MINNEAPOLIS, MN, United States, 5Radiology, University of Pennsylvania, Philadelphia, PA, United States, 6Radiology, University of Californa San Diego, San Diego, CA, United States, 7Radiology, University of Michigan, Ann Arbor, MI, United States, 8Radiology, New York University, New York, NY, United States

Synopsis

Keywords: Breast, Treatment, Cancer, Treatment Response

Motivation: Accurate imaging markers to establish pathologic complete response (pCR) during neoadjuvant chemotherapy (NACT) could enable therapy de-escalation to avoid excessive systemic treatments

Goal(s): To determine if quantitative diffusion-weighted MRI (DWI) can accurately detect pCR following NACT.

Approach: In the ACRIN 6698/I-SPY 2 multicenter trial dataset, tumor region apparent diffusion coefficient (ADC) from DWI was measured on post-NACT/presurgical MRIs. The accuracy of ADC for predicting pCR, alone and in combination with functional tumor volume (FTV) from contrast-enhanced MRI, was assessed.

Results: In multivariate models ADC accurately predicts pCR, and is influenced by field strength, spatial resolution, and lesion morphology.

Impact: Apparent diffusion coefficient measured by DWI shows promise for determining absence of residual disease following chemotherapy and may provide a non-contrast option for tailoring therapies and enabling patients to avoid unnecessary prolongation of treatment.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.

Keywords